May 21 Clinical Quick Takes: Array gains on colorectal cancer plans; plus Tocagen, Promedior

Array planning submissions for colorectal cancer triplet
Array BioPharma Inc. (NASDAQ:ARRY) gained $4.81 (23%) to $25.77 on Tuesday after interim data from the Phase III BEACON CRC trial to treat BRAF

Read the full 303 word article

User Sign In